Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.

This brief communication describes evidence which proves the beneficial effects of fenofibrate on the retinal vasculature in type 2 diabetes, acting via both lipid lowering and non-lipid lowering mechanisms. It discusses data from FIELD and other trials to support the use of fenofibrate as a secondary preventive therapy for diabetic retinopathy. These data contrast with the lack of retinal benefit shown in major cardiovascular outcome trials of other blood pressure lowering and glucose lowering agents such as empagliflozin, liraglutide, perindopril + indapamide, and ramipril.